RESEARCH AND DEVELOPMENT OF A BIOSIMILAR DRUG BASED ON THE MONOCLONAL ANTIBODY ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (Q3163420)

From EU Knowledge Graph
Revision as of 17:18, 12 October 2021 by DG Regio (talk | contribs) (‎Removed claim: summary (P836): Genhelix, SA, a company belonging to Mabxience (the Chemo Group biotechnology initiative), through the project “Research and development of a biosimilar drug based on the Adalimumab monoclonal antibody for the treatment of Rheumatoid Arthritis”, aims to develop an Adalimumab biosimilar that meets the requirements established by the regulatory agencies and which introduces substantial improvements in the formulation of the medicinal product, in...)
Jump to navigation Jump to search
Project Q3163420 in Spain
Language Label Description Also known as
English
RESEARCH AND DEVELOPMENT OF A BIOSIMILAR DRUG BASED ON THE MONOCLONAL ANTIBODY ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Project Q3163420 in Spain

    Statements

    country
    Spain
    0 references
    EU contribution
    1,223,176.5 Euro
    0 references
    budget
    2,446,353.0 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    30 November 2015
    0 references
    end time
    31 December 2017
    0 references
    beneficiary name (string)
    GH GENHELIX SOCIEDAD ANONIMA
    0 references
    beneficiary
    Q3163419
    0 references
    coordinate location

    42°38'2.94"N, 5°58'17.11"W
    0 references
    postal code
    24089
    0 references
    summary
    Genhelix, SA, empresa perteneciente a Mabxience (iniciativa biotecnológica del grupo Chemo), a través del proyecto “Investigación y desarrollo de un medicamento biosimilar basado en el anticuerpo monoclonal Adalimumab para el tratamiento de la Artritis Reumatoide”, tiene como objetivo el desarrollo de un biosimilar de Adalimumab que cumpla con los requisitos establecidos por las agencias regulatorias y que introduzca mejoras sustanciales en la formulación del medicamento, en la producción (a través de una optimización de los medios de cultivo y escalado industrial), de tal manera que sea posible alcanzar un biosimilar con un precio final inferior al 50% del actual y por lo tanto una reducción en el coste del tratamiento, facilitando su uso en los países en vías de desarrollo. (Spanish)
    0 references
    location (string)
    León
    0 references

    Identifiers

    Spanish Kohesio ID
    IDI-20160106
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3163420&oldid=12834188"